Operating Income (Loss) in USD of Aptevo Therapeutics Inc. from Q1 2015 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Aptevo Therapeutics Inc. quarterly/annual Operating Income (Loss) history and change rate from Q1 2015 to Q3 2025.
  • Aptevo Therapeutics Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$7.61M, a 46% decline year-over-year.
  • Aptevo Therapeutics Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$26.7M, a 8.52% decline year-over-year.
  • Aptevo Therapeutics Inc. annual Operating Income (Loss) for 2024 was -$24.6M, a 14.8% increase from 2023.
  • Aptevo Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$28.9M, a 0.83% decline from 2022.
  • Aptevo Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$28.6M, a 33.8% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Aptevo Therapeutics Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$26.7M -$7.61M -$2.4M -46% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 -$24.3M -$6.23M -$202K -3.35% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025
Q1 2025 -$24.1M -$6.48M +$503K +7.2% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$24.6M -$6.38M +$1K +0.02% 01 Oct 2024 31 Dec 2024 10-K 14 Feb 2025
Q3 2024 -$24.6M -$5.21M +$1.35M +20.5% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 -$26M -$6.02M +$2.15M +26.3% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025
Q1 2024 -$28.1M -$6.98M +$773K +9.97% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$28.9M -$6.38M +$1.3M +16.9% 01 Oct 2023 31 Dec 2023 10-K 14 Feb 2025
Q3 2023 -$30.2M -$6.56M +$1.22M +15.7% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$31.4M -$8.18M -$616K -8.15% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$30.8M -$7.76M -$2.15M -38.2% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q4 2022 -$28.6M -$7.68M -$3.64M -90.2% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024
Q3 2022 -$25M -$7.78M -$3.03M -63.9% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$22M -$7.56M -$1.84M -32.2% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 -$20.1M -$5.61M +$1.28M +18.5% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 -$21.4M -$4.04M +$2.78M +40.8% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 -$24.2M -$4.75M +$1.5M +24% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$25.7M -$5.72M +$1.09M +15.9% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022
Q1 2021 -$26.8M -$6.89M +$734K +9.63% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 -$27.5M -$6.82M -$1.65M -32% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022
Q3 2020 -$25.8M -$6.25M +$5.21M +45.5% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$31.1M -$6.81M +$6.09M +47.2% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 -$37.1M -$7.62M +$3.82M +33.4% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021
Q4 2019 -$41M -$5.17M +$8.43M +62% 01 Oct 2019 31 Dec 2019 10-K 31 Mar 2021
Q3 2019 -$49.4M -$11.5M +$668K +5.51% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$50.1M -$12.9M -$452K -3.63% 01 Apr 2019 30 Jun 2019 10-Q 09 Aug 2019
Q1 2019 -$49.6M -$11.4M +$2.06M +15.3% 01 Jan 2019 31 Mar 2019 10-Q 09 May 2019
Q4 2018 -$51.7M -$13.6M +$3.23M +19.2% 01 Oct 2018 31 Dec 2018 10-K 25 Mar 2020
Q3 2018 -$54.9M -$12.1M -$1.78M -17.2% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019
Q2 2018 -$53.1M -$12.4M +$2.21M +15.1% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 -$55.3M -$13.5M -$1.37M -11.3% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 -$53.9M -$16.8M -$2.27M -15.6% 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019
Q3 2017 -$51.7M -$10.3M +$80.2M +88.6% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$132M -$14.6M -$1.8M -14% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 -$130M -$12.1M +$850K +6.55% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 -$131M -$14.6M +$3.95M +21.3% 01 Oct 2016 31 Dec 2016 10-K 31 Mar 2017
Q3 2016 -$135M -$90.5M -$77.3M -586% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017
Q2 2016 -$57.5M -$12.8M +$5.47M +29.8% 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017
Q1 2016 -$63M -$13M -$1.88M -16.9% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017
Q4 2015 -$61.1M -$18.5M 01 Oct 2015 31 Dec 2015 10-K 31 Mar 2017
Q3 2015 -$13.2M 01 Jul 2015 30 Sep 2015 10-K 31 Mar 2017
Q2 2015 -$18.3M 01 Apr 2015 30 Jun 2015 10-K 31 Mar 2017
Q1 2015 -$11.1M 01 Jan 2015 31 Mar 2015 10-K 31 Mar 2017

Aptevo Therapeutics Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$24.6M +$4.28M +14.8% 01 Jan 2024 31 Dec 2024 10-K 14 Feb 2025
2023 -$28.9M -$237K -0.83% 01 Jan 2023 31 Dec 2023 10-K 14 Feb 2025
2022 -$28.6M -$7.24M -33.8% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024
2021 -$21.4M +$6.09M +22.2% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 -$27.5M +$13.5M +32.9% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022
2019 -$41M +$10.7M +20.7% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021
2018 -$51.7M +$2.28M +4.23% 01 Jan 2018 31 Dec 2018 10-K 25 Mar 2020
2017 -$53.9M +$84.8M +61.1% 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019
2016 -$139M -$77.7M -127% 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2018
2015 -$61.1M 01 Jan 2015 31 Dec 2015 10-K 31 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.